Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Implementation of case management to reduce cardiovascular disease risk in the Stanford and San Mateo Heart to Heart randomized controlled trial: study protocol and baseline characteristics | Implementation Science BioMed Central Open Access Study protocol Implementation of case management to reduce cardiovascular disease risk in the Stanford and San Mateo Heart to Heart randomized controlled trial study protocol and baseline characteristics Jun Ma Ky-Van Lee Kathy Berra and Randall S Stafford Address Program on Prevention Outcomes and Practices Stanford Prevention Research Center Stanford University School of Medicine Stanford CA USA Email Jun Ma - Ky-Van Lee - Kathy Berra - kberra@ Randall S Stafford - rstafford@ Corresponding author Published 27 September 2006 Received 24 April 2006 Accepted 27 September 2006 Implementation Science 2006 1 21 doi 1748-5908-1-21 This article is available from http content 1 1 21 2006 Ma et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Case management has emerged as a promising alternative approach to supplement traditional one-on-one sessions between patients and doctors for improving the quality of care in chronic diseases such as coronary heart disease CHD . However data are lacking in terms of its efficacy and costeffectiveness when implemented in ethnic and low-income populations. Methods The Stanford and San Mateo Heart to Heart HTH project is a randomized controlled clinical trial designed to rigorously evaluate the efficacy and cost-effectiveness of a multi-risk cardiovascular case management program in low-income primarily ethnic minority patients served by a local county health care system in California. Randomization occurred at the patient level. The primary outcome measure is the absolute CHD risk over 10 years. Secondary outcome .
